Nintedanib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 100 mg, 150 mg
Reference Brands: Ofev (USA, EU), Vargatef (EU)
Category: Oncology Cancer Care
Nintedanib is available in Capsules and strengths such as 100 mg, 150 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Nintedanib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Nintedanib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Nintedanib is an oral medication prescribed for the treatment of idiopathic pulmonary fibrosis (IPF) and certain types of non-small-cell lung cancer (NSCLC) when used in combination with other therapies. It belongs to the class of small-molecule tyrosine kinase inhibitors and works by targeting multiple growth factor receptors, including VEGFR, FGFR, and PDGFR. By inhibiting these pathways, nintedanib reduces fibroblast proliferation, slows ongoing fibrotic processes, and delays progression of irreversible tissue damage.
Sold under the brand names Ofev and Vargatef, nintedanib is available in oral capsule formulations, typically 100 mg and 150 mg. It is also indicated for systemic sclerosis-associated interstitial lung disease and progressive fibrosing interstitial lung disease, making it a critical therapy for patients with progressive fibrotic conditions.
Nintedanib therapy requires careful patient monitoring due to potential adverse effects, including liver enzyme elevations and gastrointestinal issues. Its pharmacokinetic profile allows for targeted, individualized treatment, and understanding drug interactions is essential to optimize efficacy and safety. Nintedanib provides clinicians with an effective option to manage fibrotic lung diseases and certain cancers, supporting improved patient outcomes and delaying disease progression.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Nintedanib is used to treat idiopathic pulmonary fibrosis (IPF) and certain types of lung cancer. It helps slow disease progression and is prescribed for adults with progressive fibrotic lung disease or as part of combination therapy for specific cancers.
Nintedanib is a small-molecule tyrosine kinase inhibitor that targets multiple receptors, including VEGFR, FGFR, and PDGFR, inhibiting pathways involved in fibrosis and tumor growth.
The main trade names are Ofev and Vargatef.
Nintedanib is manufactured and marketed by Boehringer Ingelheim.
The generic name is nintedanib.
The brand names are Ofev and Vargatef.
Nintedanib is manufactured in Europe and the United States under strict quality standards by Boehringer Ingelheim.
Related Products
Momelotinib
Strength:
100 mg, 150 mg, 200 mg
Form: Tablets
Reference Brands: Ojjaara (USA)
View Details
Nirogacestat
Strength:
50 mg
Form: Tablets
Reference Brands: Generic formulations marketed under different names
View Details
Quick Response Guaranteed | Verified Suppliers
